Global & China Rigid Endoscopes Market to 2031

China boasts a vast healthcare infrastructure and a robust domestic manufacturing sector. Rigid endoscopes are extensively utilized in urology, gynecology, ENT, and general surgery, particularly within tertiary hospitals and urban surgical centers. The country's emphasis on minimally invasive techniques has spurred the adoption of rigid endoscopes featuring HD and 4K imaging systems, particularly in laparoscopic and hysteroscopic procedures. Key factors driving the market include a growing number of endoscopic procedures across various specialties and an increase in regulatory approvals for locally produced rigid scopes. For example, a study published in the Chinese Medical Journal in September 2025 reported that hospitals in China conducted approximately 9,433 digestive endoscopic procedures in 2023. This statistic highlights the expansion of gastroenterology and endoscopy services nationwide, contributing to higher early cancer detection rates due to improved diagnostic capabilities. Furthermore, major industry players are actively pursuing regulatory approvals, which is further fueling market growth in China. In August 2025, Olympus Corporation announced it had received its first Medical Device Registration Certificate from the Jiangsu Medical Products Administration for its GIF-EZ1500-C gastroscope, marking the first locally manufactured advanced imaging endoscope certified in China, produced at Olympus (Suzhou) Medical Device Co., Ltd. The high incidence of conditions such as kidney stones, uterine fibroids, and ENT disorders drives clinical demand. Hospitals are increasingly utilizing rigid ureteroscopes and hysteroscopes for both diagnostic and therapeutic purposes, citing enhanced procedural control and shorter recovery times. In the ENT field, rigid nasal endoscopes are frequently employed in sinus surgeries and tumor resections, supported by growing expertise in endoscopic skull base procedures. As China continues to invest in surgical modernization and improving healthcare access, the market is expected to remain clinically significant and foster innovation. Show more